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Designer nucleases, like zinc-finger nucleases (ZFNs), represent valuable tools for targeted genome editing.
Here, we took advantage of the gamma-retroviral life cycle and produced vectors to transfer ZFNs in the
formofprotein,mRNAandepisomalDNA.TransferefficacyandZFNactivitywereassessedinquantitative
proof-of-conceptexperimentsinahumancelllineandinmouseembryonicstemcells.Wedemonstratethat
retrovirus-mediated protein transfer (RPT), retrovirus-mediated mRNA transfer (RMT), and
retrovirus-mediated episome transfer (RET) represent powerful methodologies for transient protein
deliveryorproteinexpression.Furthermore,wedescribecomplementarystrategiestoaugmentZFNactivity
after gamma-retroviral transduction, including serial transduction, proteasome inhibition, and
hypothermia. Depending on vector doseand targetcell type, genedisruption frequencies of up to 15% were
achieved with RPT and RMT, and .50% gene knockout after RET. In summary, non-integrating
gamma-retroviral vectors represent a versatile tool to transiently deliver ZFNs to human and mouse cells.
N
uclease-mediated genome modification has evolved into an indispensable tool for basic research, bio-
technology and therapeutic applications
1. In particular, designer nucleases have been used for nucleo-
tide-specific gene modification, gene disruption, and targeted deletion or insertion at selected loci.
Various classes of designer nucleases have been described, including meganucleases
2, zinc-finger nucleases
(ZFNs)
3, transcription activator-like effector nucleases (TALENs)
4, and RNA-guided endonucleases
5. Of these,
the ZFNs have been the most widely exploited thus far and are currently being investigated in a clinical trial that
aims to generate autologous T cells resistant to HIV infection (e.g. NCT00842634). ZFNs are designed in pairs,
with each subunit consisting of a sequence-specific DNA binding domain that is linked to a DNA cleavage
domain. Hence,an active ZFN is formed following targeted binding and heterodimerisation of the ZFN subunits
onoppositestrandsoftheDNAhelix
6,7.TheDNAbindingdomaintypicallyencompasses3to4zincfingers,each
of them recognising a nucleotide triplet. When both subunits bind to the target site, the DNA is cut in the spacer
sequence that separates the two target half-sites. Improvements in ZFN technology that aimed at increasing
specificity and reducing ZFN-associated toxicity included better platforms to generate the DNA binding
domains
8, the development of obligate heterodimeric FokI cleavage domains
9–11, and the characterisation of
optimal linker/spacer combinations
7,12.
The ZFN technology has been successfully applied in a variety of organisms
13 and primary human cells,
including T cells
14, hematopoietic stem cells
15, mesenchymal stromal cells
16,17, keratinocyte stem cells
18, and
pluripotent stem cells
19,20. Careful and accurate genome editing is particularly attractive for autologous stem
cells,whichafterexvivogenecorrectioncanbetransplantedbackintothepatient.However,currentgenetransfer
methods,whichenablethetransientexpressionofdesignernucleasesinhumanstemcells,canbeassociatedwith
high toxicities and/or low delivery efficiencies, thus presenting a major hurdle in the preparation of autologous
gene corrected cells
21. To overcome this obstacle, viral vector systems, like integrase-deficient lentiviral vectors
(IDLVs),adenoviralvectors(AdV),andvectorsbasedonadeno-associatedviruses(AAVs)havebeensuccessfully
employed
14,22–25. Whilst nuclease expression levels from non-optimised IDLVs can be low
26, AdV and AAV
vectors have displayed restricted cell tropism.
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in several gene therapy studies
27,28. As their parental virus, these
vectors are enveloped and contain two copies of a plus-stranded
RNA genome, which is capped and polyadenylated like a cellular
mRNA. The viral nucleic acid in association with nucleocapsid
(NC) proteins is surrounded by a shell of capsid proteins, which in
turnisenclosedbyanenvelopederivedfromthehostcellmembrane.
The viral matrix (MA) proteins are located between the capsid and
the envelope (reviewed in 29). Retroviral vectors typically enter cells
in a receptor-mediated manner. In the cytoplasm, the retroviral
particles uncoat and reverse transcribe the plus-stranded RNA gen-
ome into a double-stranded linear proviral DNA. Upon completion
of reverse transcription, a preintegration complex (PIC) containing
viral DNA and cellular proteins is formed. During mitosis, the dis-
solution of the nuclear membrane allows the PIC to move into the
nucleus where the viral integrase mediates integration of proviral
vector DNA into the cellular chromosome
29.
It has recently been shown that non-integrating retroviruses can
serve as molecular tools for the efficient delivery of mRNA
30 or
proteins
31,32. The retrovirus-mediated mRNA transfer (RMT) tech-
nologyisbasedonmutationswithinthevector’sprimer-bindingsite,
which prevents the reverse transcription of viral mRNA
33. This
approach has been exploited for the transient delivery of marker
proteins and enzymatically active proteins, such as recombinases
and transposases
30,34,35. Retrovirus-mediated protein transfer (RPT)
hasbeenachievedbyfusingaforeignopenreadingframeateitherthe
39-end of the NC or MA coding sequences, or at the 59-end of the
viral p12 reading frame
31. Inclusion of a protease cleavage site
ensures that the foreign protein is released from NC or MA by the
viral protease during maturation of the vector particles
31.
In the present study we demonstrate that by exploiting retroviral
particles as delivery vehicles for ZFN proteins, ZFN-encoding
mRNA, and DNA episomes, we can induce stable genetic modifica-
tions in a human cell line and in mouse pluripotent stem cells. We
show that all three vector systems, RPT, RMT and RET, can effi-
ciently deliver a marker protein to the target cells. Furthermore, we
provide evidence of high gene knockout frequencies after transient
delivery of ZFNs without eliciting significant cytotoxic side-effects.
Results
Efficient delivery of a marker protein by non-integrating retro-
viral particles. We constructed various retroviral vector scaffolds
that allowed us to express a transgene using either RET or RMT
particles. Moreover, the DsRed-Express (DsRex) maker protein or
ZFNs were delivered by RPT through fusion of the marker to gag
(Figure1A).Efficienttransgenedeliverywasvalidatedbymonitoring
DsRex expression 1, 2 and 5 days post-transduction of the human
chronic myelogenous leukaemia cell line K562, in which we intro-
duced a single copy EGFP expression cassette in the AAVS1 locus
(K562-EGFP).Theinfluenceoftemperatureontransgeneexpression
was investigated by incubating the transduced K562-EGFP cells at
either 30uC (hypothermia) or 37uC (normothermia). Up to 35% of
cells were DsRex positive, and levels from all non-integrating deli-
very methods were significantly higher and persisted longer under
hypothermic as compared to normothermic conditions (Figure 1B).
In contrast, DsRex expression from integrating vectors was detected
earlier and at a higher level at 37uC.
To examine dose response and kinetics of protein expression,
K562-EGFP cells were transduced with increasing amounts of the
DsRex expressing vectors. After transduction, cells were maintained
at 30uC for 7 days before being transferred to 37uC. Flow cytometric
analysis revealed a positive correlation between vector dose and
DsRex levels (Figure 1C). The highest transduction frequencies were
reached with the RPT vectors, which showed delivery of DsRex in
almost 100% of cells. Furthermore, DsRex expression from RET,
RMT and RPT vectors remained stable during incubation at 30uC,
but declined rapidly after transferring the cells to 37uC. This was in
sharp contrast to the results obtained for the integrating vector,
which showed reduced expression under hypothermic conditions,
which then increased under normothermic conditions.
Retroviral mediated ZFNdelivery allows for stable geneknockout
in a human cell line. Next we used the above-described systems to
deliveractiveZFNstargetedtotheEGFPgene
8.Inordertoassessthe
activities and toxicities of these ZFN delivery vectors, we transfected
the various vector plasmids into an U2OS cell line that carries 3
copies of a destabilised EGFP transgene
24. ZFN mediated EGFP
disruption could be detected from all retroviral vector backbones
by flow cytometry (Figure S1, A). Because maturation of viral
proteins takes place in the virus particles, we did not detect
‘‘mature’’ ZFN proteins in the transfected cells in case of the RPT
vectors but only ‘‘ZFN precursors’’ fused to the gag proteins (Figure
S1, B). Moreover, ZFN activity correlated positively with plasmid
dose and negatively with cell survival, an indirect measurement of
ZFN-associated toxicity (Figure S1, C).
Encouraged by these results, various gamma-retroviral particles
were produced and used to transduce K562-EGFP cells. The human
cell line was co-transduced with retroviral vectors expressing either
ZFN subunit at an MOI of 2.5 and EGFP knockout was assessed
following incubation of cells at 30uCo r3 7 uC at days 2 and 5 post-
transduction. We observed only weak knockout activity of transi-
entlyexpressedZFNunderhypothermicconditionsandthedifference
between EGFP disruption frequencies at 30uC and 37uC was not
statistically significant (Figure 2A). In agreement with marker pro-
tein expression (Figure 1B), ZFN activity from integrating vectors
was higher at 37uC (Figure 2A). To investigate the correlation
between vector dose and ZFNs activity, K562-EGFP cells were trans-
duced with MOIs of 2.5, 25 and 250. The cells were initially main-
tained at 30uC for 7 days, and then transferred to normothermia.
Even atthe highest vector dose,ZFN activity wasnotdetectable from
RMT and RPT vectors. However, .50% gene knockout activity was
detected in cells following transduction with the RET and IRV vec-
tors (Figure 2B).
To validate efficient production, packaging, and processing of the
ZFNs incorporated in the retroviral vector particles, we performed
Western blot analysis of the virus supernatants and the lysates of the
producer cells. Assessment of the producer cells indicated the pres-
ence of ZFN proteins in all producer cell lysates (Figure 2C). As
expected, the ZFNs detected in the cell lysates of RPT particle pro-
ducing cells were mainly present as fusions to either gag or gag/pol
precursor proteins. Equal protein loading was confirmed by staining
with an anti-b-actin antibody. Importantly, analysis of the retroviral
particles in the supernatant revealed the presence of mature ZFN
proteins in both the NC and MA RPT vector variants (Figure 2C),
confirming efficient proteolytic cleavage of the ZFN proteins from
theirNCorMAcarriers.Asexpected,RMTandIRVparticlesdidnot
contain any ZFN proteins. Unexpectedly, the RET particles con-
tained marginal amounts of ZFN proteins, possibly as a result of
cross-packagingduetothehighZFNconcentrationsintherespective
producer cells. Visualisation of the viral capsid protein p30 con-
firmed equivalent loading of virus particles (Figure 2C).
Triple transduction or proteasome inhibitor enhances ZFN-
mediated knockout. Having confirmed that ZFN proteins were
efficiently produced and/or properly processed within the retrovi-
ral particles, we hypothesised that low ZFN activity after cell trans-
ductionmayresultfrominsufficientintranuclearZFNconcentrations
and/or rapid protein degradation. To test this hypothesis, we per-
formed three serial consecutive transductions (every 24 h for 3 days)
in K562-EGFP cells using a low vector dose. In addition we per-
formed a single transduction in combination with the proteasome
inhibitor MG132. As compared to a single transduction, repeti-
tive infections of cells increased the level of ZFN-mediated gene
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 4656 | DOI: 10.1038/srep04656 2Figure 1 | Retrovirus-mediated transgene delivery to human cell line. (A) Schematic of packaging system. Displayed are the cis and trans-acting
retroviral elements used to generate retroviral particles. Cis elements: retroviral vector genomes containing a gene of interest (GOI) flanked by the long
terminalrepeats (LTRs),aprimerbindingsite(PBS)andthewoodchuck hepatitisposttranscriptional regulatoryelement (WPRE). Transelements: viral
sequences encoding gag and pol genes under the cytomegalovirus (CMV) promoter. To produce integrating retroviral vector (IRV), unmodified
recombinant cis and trans-acting elements were used. For the production of retroviral episomal vectors (RET), an integrase (IN)-defective variant (IN*)
of the gag/pol plasmid was utilised. For retrovirus-mediated mRNA transfer (RMT), a normal gag/pol was combined with a vector genome containing a
mutated primer binding site (aPBS). For retrovirus-mediated protein transfer (RPT), only the trans-acting components were used, which contained the
GOI fused to C-terminus of either the nucleocapsid (NC) or the matrix (MA) protein encoding sequences. The GOI was separated from NC or MA by a
retroviralproteasecleavagesite.pA,polyadenylationsignal;p12,viralp12protein;CA,capsid;PR,protease;RT,reversetranscriptase.(B)DsRed-Express
(DsRex)expressioninK562-EGFPcellsundernormalandhypothermicconditions.CellsweretransducedwithretroviralvectorsexpressingDsRex(MOI
of2.5)andincubatedat37uCorat30uC.Thepercentageofredcellswasmeasuredbyflowcytometryatday1,2and5post-transduction.Asterisksindicate
statisticallysignificant differencebetweenpairedsamples(37uCvs.30uC;p,0.05;experiment repeatedthreetimesinduplicate).(C) Kineticsanddose-
dependent expression of DsRex in K562-EGFP cells. Cells were transduced with increasing doses of retroviral vectors (MOI of 2.5, 25, 250). After
transduction, cells were kept at 30uC for 7 days then transferred to 37uC for the rest of the experiment. Expression of DsRex was measured by flow
cytometry at indicated time points.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 4656 | DOI: 10.1038/srep04656 3Figure 2 | ZFN-mediated knockout in K562-EGFP cells. (A) Temperature dependent EGFP knockout. Cells were transduced with retroviral vectors
(MOIof2.5)andincubated at37uCo r3 0uC.The declineinEGFPexpression wasmeasured byflow cytometry atday 2and5post-transduction. Asterisk
indicates statistically significant difference between paired samples (30uC vs. 37uC; p , 0.05; experiment repeated three times in duplicate). (B) Kinetics
and dose-dependence of EGFP knockout. Cells were transduced with increasing doses of retroviral vectors (MOI of 2.5, 25, 250) and kept at 30uC for 7
daysbeforethetransferto37uCfortherestoftheexperiment.PercentageofEGFPpositivecellswasmeasuredbyflowcytometryatindicatedtimepoints.
(C) Analysis of ZFN expression. ZFN proteins were detected with anti-HA tag antibody. As loading controls, antibodies against b-actin (cell lysates) or
p30(retroviralsupernatants)wereused.(D)EffectofmultipleretrovirustransductionsandofproteasomeinhibitorMG132.Cellsweretransduced1,2or
3timeswithretroviralvectorsexpressingZFNconstitutively(IRV)ortransiently(RET,RMT,RPT-NC,RPT-MA)usinganMOIof2.MG132wasadded
to the cell medium after a single retrovirus transduction. EGFP expression was measured 3–4 days after the last transduction. Significant increase in the
percentageofEGFP-negativecellsbetweensingleandmultipletransductionsandMG132treatmentforthesamevectortypeismarkedwithanasterisk(p
, 0.05). (E) Genotyping of ZFN-treated K562-EGFP cells. Genomic DNA of triple transduced cells was used as a template for PCR amplification of the
ZFN-modified EGFP locus before digestion with the mismatch-sensitive T7 endonuclease I (T7E1). The expected product lengths are indicated on the
right.OpentrianglesindicateanunspecificDNAfragmentinundigestedsamples.IRV,integratingretrovirusvector;RET,retrovirus-mediatedepisomal
transfer;RMT, retrovirus-mediated mRNAtransfer; RPT,retrovirus-mediated proteintransfer;NC, nucleocapsidposition ofthe transgene;MA,matrix
localisation of a transgene; L, left domain of ZFN; R, right domain of ZFN. Mock values were subtracted from samples in each experiment.
www.nature.com/scientificreports
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gene disruption could be increased to approximately 15% with the
repetitive transduction scheme. Furthermore, the use of a protea-
some inhibitor was particularly beneficial for RPT mediated EGFP
knockout. With the RPT-MA vector, the percentage of EGFP nega-
tive cells increased by 3-fold when compared to non-treated cells,
reaching knockout frequencies of ,10% (Figure 2D). To assess whe-
ther the treatment with proteasome inhibitors also improves gene
disruption if the ZFN are delivered in the form of mRNA, K562-
EGFP cells were nucleofected with synthetic mRNAs encoding the
ZFNs and treated with 0.5 mM of MG132. Results show that the
proteasome inhibitor enhanced ZFN-mediated EGFP knockout by
15-fold, resulting in ,29% of cells being EGFP negative (Figure S2).
To confirm that the decrease in EGFP expression was due to ZFN
activity,weperformed aT7endonucleaseI(T7E1)assayongenomic
DNA isolated from triple transduced K562-EGFP cells. A genomic
fragmentencompassingtheZFNtargetlocuswasPCRamplifiedand
subjected to treatment with T7E1 (Figure 2E). The results corre-
sponded well with the flow cytometric data and showed that the
percentage of mutated EGFP alleles was highest after transduction
with IRV and RET vectors.
Retroviral ZFN delivery allows for stable gene knockout in
pluripotent stem cells. To validate our delivery systems in a stem
cell line, the vectors were applied to mouse embryonic stem cells
(mESCs) carrying a single copy of the EGFP gene in the HPRT
locus (mES-EGFP). Transduction with non-integrating vector sys-
tems led to higher amount of DsRex-positive cells compared to the
integrativevector.Upto,30%ofDsRex-positivecellsweredetected
and the marker could be detected longer under hypothermic
conditions (Figure 3A). Moreover, we observed a linear correlation
between the percentage of DsRex-positive cells and the vector dose
(Figure S3). After a single round of transduction with the ZFN
delivery vectors, substantial levels of EGFP knockout could only be
detected with the integrating vector (Figure 3B). While the use of a
proteasome inhibitor did not affect gene disruption rates in mES-
EGFP cells, a triple transduction with a low dose of RET and RPT
particles(MOIof2)resultedin9–15%EGFP-negativecellsandupto
52% with the integrating system (Figure 3C). Determination of
vector copy numbers revealed that about 10 integrated (IRV) or
episomal (RET) genome copies are sufficient to achieve these
knockout frequencies (Figure S4).
To assess potential toxicity of the ZFN delivery vectors, we
assessed general cell survival and conducted a cell cycle analysis
following single and triple transductions. While a dose-dependent
toxicity stemming from viral transduction was observed, ZFN
expression did not induce any additional cytotoxicity (Figure S5).
Cell cycle plots of mES-EGFP cells 24 h after a single transduction
with integrating or episomal retroviral particles revealed a weak G2/
M arrest for IRVs (Figure 3D), however, no significant differences in
the cell cycle profiles were observed after transient ZFN delivery by
RET, RMT and RPT.
Discussion
Since the first generation of artificial ZFNs
36, they have been deve-
loped for a large variety of biomedical applications
37. Although ZFN
represent a powerful tool in genome engineering, their transfer into
primary cells has remained a challenge. To overcome this hurdle,
ZFNshavebeenvectorisedintovariousviralsystems,includingthose
based on the adeno-associated virus
23–25, integrase-deficient lenti-
virus vectors (IDLV)
22, adenoviral vectors
14, and baculovirus
38.
Moreover, microinjection of mRNA encoding ZFNs into one-cell
zebrafish and rat embryos proved efficient for the disruption of
endogenous genes
39–41. More recently, direct protein transfer of
ZFN has been shown to successfully create a gene knockout in
human cells with minimal toxicity
42. With the exception of IDLVs,
the above-mentioned viral vector systems have a restricted cell trop-
ism,andmRNAor proteinbasedZFNtransfer maynotbeamenable
forlarge-scaleapproaches.Here,weaimedatscrutinisingtheefficacy
and safety of transient ZFN delivery by vectors based on the non-
integrating gamma-retrovirus. We demonstrate in a human cell line
and in mouse pluripotent stem cells that all gamma-retroviral vector
systems employed, i.e. transfer of DNA episomes, mRNA or protein,
allow for the efficient transfer/expression of a marker protein.
Significant ZFN-mediated gene disruption activity was observed
with all vector systems in a human cell line, but efficient gene dis-
ruption in mES-EGFP cells was only achieved with RET based ZFN
transfer.
Itisknownthatafewhundredretroviralparticlescanenteragiven
target cell
31. Although we observed a linear correlation between the
applied vector dose and expression of the reporter protein DsRex,
this observation could not be extended to ZFN activity. This is most
likelybecauseacertainthresholdconcentrationofintranuclearZFNs
isrequiredforoptimalactivity.Here,weidentifiedthreeaccompany-
ingstrategiestoincreaseZFNactivityinretrovirallytransducedcells:
aserial transduction scheme,hypothermia, and inhibition of protea-
some mediated degradation. It has previously been shown that
repeated retrovirus transduction of hematopoietic stem cells aug-
ments transgene expression levels
43. In accordance with these find-
ings our data demonstrates that triple transduction of K562-EGFP
cells and mES-EGFP using low retroviral vector doses significantly
improved ZFN activity, leading to higher EGFP disruption rates. Of
note, quantitative determination of retroviral genome copies
revealed that 2 to 10 episomal copies of the ZFN expression vector
are sufficient to achieve gene knockout frequencies in the double-
digit range.
It has also been reported that a transient cold-shock can enhance
ZFN activity following cell transfection
44, though the mechanism
behind this observation has remained undefined. Based on our
results we cannot draw any definite conclusions about the impact
of hypothermia on ZFN activity, however, our data on the transfer
efficiency of amarker gene/protein suggests that transient hypother-
mia extends the half-life of the non-integrating viral vector systems
inthecell.Thisisinlinewithapreviouslyreportedobservation
45,but
itisimportanttomentionthatexpressionfromtheintegratingretro-
viral vector was considerably higher at normothermia
46. Hence, to
establishthedirect effectoftemperatureontheretrovirallifecyclein
general, and on retrovirus-mediated ZFN delivery in particular, fur-
ther experiments will be needed.
TopreventrapidZFNturnoverwithintransducedcells,wetreated
infected cells with the proteasome inhibitor MG132. Two studies
havepreviouslyreportedonthebeneficialeffectofMG132treatment
with retroviral and lentiviral based gene transfer in human and
mouse cells
34,47. Moreover, it has been shown that the proteasome
inhibitor MG132 increases the stability of zinc-finger proteins upon
cell transfection
48,49 and enhances gene disruption rates in a cell
line
49. The results obtained in this report revealed a beneficial effect
of proteasome inhibition on ZFN-mediated knockout efficiencies in
K562-EGFP cells transduced with RMT and RPT vectors or nucleo-
fected with synthetic mRNA. On the other hand, MG132 had no
noticeable effect on ZFN activity in mES-EGFP cells. We speculate
that the fast proliferation rate of these cells leads to rapid ZFN dilu-
tion.Alternatively,thefeedercellsmaycompromisebothviraltrans-
duction efficiency
50 and the effect of MG132. Indeed, in comparison
to somatic cells, mouse ESCs display some unique cell cycle features,
like a very short G1 phase and the lack of a G1/S checkpoint
51. Most
of the ESCs reside in the S phase (60–70%) and the duration of a cell
cycle (10–12 h) is extraordinarily short
51,52. We observed a weak G2/
M phase arrest in mES-EGFP cells transduced with integrating ZFN
expression vectors, indicative of DNA damage. Similar observations
were made previously after treatment of ESCs with DNA damage-
inducing agents, like ionising radiation
52. The absence of cell cycle
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 4656 | DOI: 10.1038/srep04656 5Figure 3 | RetrovirusmediatedZFNdeliverytoknockoutEGFPinmouseembryonicstemcells.mES-EGFPcellscontainingonecopyoftheEGFPgene
were transduced with retroviral vectors expressing either DsRex or ZFN as an integrating vector (IRV) or transiently (RET, RMT, RPT-NC, RPT-MA).
DsRex expression and EGFP knockout levels were measured by flow cytometry at indicated time points. (A) DsRex expression in mES-EGFP cells under
normal or hypothermic conditions. After transduction with retroviral vectors (MOI of 2.5), cells were incubated at either 37uCo r3 0 uC for 5 days. The
percentage of red cells was measured by flow cytometry at day 1, 2 and 5 post-transduction. Asterisks indicate statistically significant difference between
pairedsamples (37uCvs. 30uC;p,0.05; experiment repeatedthree timesinduplicate). (B)Kineticsanddose-dependence ofEGFPknockout inmESCs.
mES-EGFPcellsweretransducedwithincreasingdosesofretroviralvectors(MOI2.5,25,250)andkeptat30uCfor5daysbeforebeingshiftedto37uCfor
the rest of the experiment. The percentage of EGFP-negative cells was measured by flow cytometry at the indicated time points. (C) Effect of serial
transductions and of proteasome inhibitor MG132. Cells were transduced 1, 2 or 3 times with ZFN delivering retroviral vectors (MOI of 2). MG132 was
added to the cell medium after a single retrovirus transduction for 12 h. EGFP expression was measured 3–4 days after the last transduction. Significant
increase inthepercentage ofEGFP-negativecells betweensingleandmultiple transduced orMG132 treatedcells,respectively, ismarked byasterisk( p,
0.05). (D) Cell cycle analysis of mES-EGFP cells. Single or triple transduced mES-EGFP cells were labeled with BrdU and stained with APC-conjugated
anti-BrdU antibody and 7-AAD after fixation and assessed by flow cytometry. Graphs display average values of the percentage of cells captured in the
different cell cycle stages. IRV, integrating retrovirus vector; RET, retrovirus-mediated episomal transfer; RMT, retrovirus-mediated mRNA transfer;
RPT, retrovirus-mediated protein transfer; NC, nucleocapsid position of the transgene; MA, matrix localisation of the transgene. Mock values were
subtracted from samples in each experiment.
www.nature.com/scientificreports
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underscores the notion that continuous ZFN expression can lead to
significantDNAdamage.Moreover,stableintegrationofatransgene
cassette is intrinsically associated with a higher risk of insertional
mutagenesis and malignant transformation
53. Hence, the non-integ-
rating delivery platforms described here may offer a suitable alterna-
tive for transient ZFN expression in many mammalian cell types.
On the whole, we obtained considerable gene disruption efficien-
cies for all the transient-delivery retroviral vectors without the need
of selection. Further improvements need to be made to increase the
transduction efficiency of target cells. In the context of retroviral
vectors this can be achieved by modifying the vector envelope with
a cell type specific ligand, for which receptors are present on the
target cell surface in a great abundance. Such an approach will not
only ensure cell specific uptake of the vector but may also enable
higher concentration of the ZFN, leading to improved activity.
Finally, the retroviridae family is known to be exceptionally amend-
able to pseudotyping
54. Various studies have shown increased spe-
cificity of gene transfer with vectors pseudotyped with RD114
glycoprotein to various stem cells
55,56, pseudotyping with measles
virus glycoprotein to target plasma cells
57, or display of antibodies
or DARPins to transduce hematopoietic progenitor cells or cancer
cells
50,58.
The work presented here introduces a novel concept for ZFN
delivery to cells by means of non-integrating gamma-retroviral vec-
tors. In our study, we demonstrated the versatility of this platform in
obtainingtargetedgeneknockoutsinahumancelllineandinmurine
embryonic stem cells. Importantly, when assessing toxic side effects
ofourapproach,weshowedthatunlikeintegratingretroviralvectors,
the vectors used for transient ZFN expression do not alter the cell
cycle profile in the transduced cells. In conclusion, our versatile
gamma-retroviral ZFN transfer system allows researchers to deliver
ZFNsintheformofDNA,mRNAandprotein,therebyenlargingthe
toolbox available to genome engineers and offering novel attractive
ways of ZFN delivery for various biological applications.
Methods
Plasmids. For this study, codon-optimised (Mr. Gene; Regensburg, Germany)
zinc-finger arrays targeting EGFP gene at position 292
8 were fused to the obligate
heterodimeric FokI variant EA-KV
9 by the 4 AA linker LRGS
12. Plasmids for
gamma-retroviral vector production were derived from pRSF91
35 or pMLV
31.
Plasmids for the production of integrating vectors (IRV) and vectors for
retrovirus-mediated mRNA transfer (RMT) were generated by replacing the Flpo
gene in pRSF91.Flpo.gPRE and pRSF91.aPBS.Flpo.gPRE
30 with ZFN and DsRex,
respectively. Vector plasmids for retroviral-mediated protein transfer (RPT-NC,
RPT-MA) were generated by replacing the EGFP gene in pcDNA3.NC.Prot.GFP
and pcDNA3.MA.Prot.GFP
31 with ZFN or DsRex. All plasmid sequences can be
obtained upon request.
Cells. A human chronic myelogenous leukaemia cell line (K562) stably expressing
an EGFP gene from the AAVS1 locus was prepared by nucleofection of K562 cells
(ATCC) with the pAAVS1_SA2APuro_PGK_EGFP_HSVtkpA plasmid (created
by cloning PGK-EGFP-HSVtkpA cassette into Addgene plasmid #22075) along
with AAVS1-specific ZFN expression plasmids
19. After initial selection with
0.5 mg/ml of puromycin (Invitrogen), single cell clones were analysed by PCR and
a clone containing a single targeted integration of the EGFP expression cassette
was chosen for further experiments. K562-EGFP cells were cultured in RPMI
medium (Gibco/Life Technologies) supplemented with 10% FCS (Gibco/Life
Technologies), 100 IU penicillin and 10 mg/ml streptomycin (P/S; PAA
Laboratories GmbH, Austria), and 2 mM L-glutamine (PAA Laboratories). The
murine embryonic stem cell line BK4-G3, containing a single copy of the EGFP
gene in the HPRT locus, has previously been described
20. Cells were grown on
gamma-irradiated mouse embryonic fibroblasts (MEFs) in knockout DMEM
(Gibco/Life Technologies) supplemented with 15% FCS (PAN Biotech, Berlin,
Germany), leukaemia inhibitory factor (LIF)-conditioned medium produced from
recombinant Chinese hamster ovary cells (diluted 15500), P/S, 2 mM L-
glutamine, 0.1 mM non-essential amino acids (PAA Laboratories), and 0.1 mM b-
mercaptoethanol (Gibco/Life Technologies).
Gamma-retroviral particles. Retroviral supernatants pseudotyped with vesicular
stomatitis virus glycoprotein (VSV-G) were produced by transient transfection of
293T cells
31,35. Supernatants were collected 36 h and 60 h after transfection and
concentrated by ultracentrifugation at 82,7403 g and 4uC for 2 h. Virus pellets from
two 10 cm plates were resuspended in 300 ml of PBS and frozen in small aliquots at
280uC. For titration 8 3 10
4 U2OS-EGFP cells containing three copies of an EGFP
gene
25 were transduced with serial dilutions of concentrated virus supernatants for
1 h by centrifugation at 2003 g in the presence of protamine sulphate (4 mg/ml;
Sigma-Aldrich), followed by incubation with viruses for another 12–16 h. The
percentage of EGFP-negative or DsRex-positive cells was measured by flow
cytometry 24–48 h after transduction. The number of transducing units was
calculatedusingtheformula:(No3Nt)/D,whereNostandsforpercentageofEGFP-
negative/DsRex-positive cells, Nt the number of transduced cells, D the dilution
factor
59. K562-EGFP cells were transduced using the spinoculation method. Briefly,
48-well plates were covered with Retronectin (Takara, Otsu, Japan). Concentrated
virus supernatant (MOI of 2.5, 25 or 250) was added in 200 ml of culture medium
without FCS, and plates centrifuged at 4003 g at 4uC for 30 min. 1 3 10
5 cells in
100 ml of serum-free RPMI medium containing 4 mg/ml protamine sulphate were
added per well before centrifugation at 2003 g at 30uC for 1 h. Then, wells were
supplemented with 100 ml of RPMI medium with FCS to obtain a final serum
concentration of 10%. For the triple transduction protocol, cell transductions were
repeated every 24 h. Where indicated, the proteasome inhibitor MG132
(Calbiochem) was added to medium at 0.5 mM overnight. Murine ES-EGFP cells
weretransducedin24-wellplatescoatedwith0.1%porcinegelatine(Sigma-Aldrich).
Cells were trypsinised and feeders removed by using 70 mm cell filters (Millipore). 1
3 10
5 cells in 100 ml of serum-free ES medium was added to wells containing
retrovirus supernatants (MOI 5 2.5, 25 or 250) and protamine sulphate (4 mg/ml) in
a total volume of 400 ml. Cells were centrifuged at 2003 g for 1 h at 30uC. Then,
200 ml of complete mES medium containing ES-FCS was added to obtain a final
serum concentration of 15%. In case of multiple transductions, the first and second
transductions were performed on feeder cells. For the third transduction cells were
trypsinised and re-plated on a 12-well plate covered with 0.1% gelatine. Where
indicated, cells were incubated at 30uC, otherwise at 37uC.
Western blotting. Protein detection from cell lysates and concentrated retroviral
supernatants was performed as previously described
34 with minor adjustments.
Briefly, U2OS-EGFP cells transfected with ZFN expression plasmids were harvested
48 h after transfection, while 293T producer cells were collected 60 h post-
transfection. Cells were lysed in 100 ml of ice-cold RIPA buffer composed of 50 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% sodium dodecyl sulphate (SDS), 0.5%
sodium deoxycholate, 1% Nonidet P-40 and a cocktail of protease inhibitors
(Complete Mini, Roche Applied Science). Samples were separated by SDS-
polyacrylamide gel electrophoresis (12%) and transferred to polyvinylidene
difluoride membranes. ZFN and EGFP expression was detected using antibodies
directedagainsttheHAtag(NB600-363;NovusBiologicals,Littleton,CO)andEGFP
(MAB3580; Millipore, Billerica, MA), respectively. Control staining was performed
using anti-a-actin (sc-81178, Santa Cruz Biotechnology) or anti-p30 antibodies
(kindly provided by Sandra K. Ruscetti, NCI Frederick, MA, USA). Proteins were
visualised after staining with HRP-conjugated mouse anti-rabbit, (Dianova) mouse
anti-rat (Dianova), or donkey anti-goat (Santa Cruz) secondary antibody using the
WestPico Chemiluminescence substrate (Thermo Scientific).
Genotyping. ZFN-mediated EGFP disruption was analysed on a genomic level in
K562-EGFP cells using the T7endonuclease I (T7E1) assay as previously described
20.
Briefly, 100 ng of genomic DNA was used in a PCR reaction to amplify a 556 bp
fragment of the EGFP locus, with primers#154 59-CTACGGCAAGCTGAC-
CCTGAA (forward) and #155 59-GAACTCCAGCAGGACCATGT (reverse) using
Phusion High Fidelity DNA polymerase (Thermo Scientific). 100 ng of purified
amplicon was subjected to T7E1 digestion (5 U, New England Biolabs) for 20 min at
37uC in NEB buffer 2, before separation on a 2% agarose gel. Quantification of the
cleavage was performed using the Quantity One software (Bio Rad).
Cellcycleanalysis.K562-EGFPandmES-EGFPcellsweretransducedwithretroviral
vectorsatanMOIof2.After24 h1 mMofBrdUwasaddedtothecellculturemedium
for45 min(K562-EGFP)or20 min(mES-EGFP).AfterwashingwithPBS,cellswere
harvested, fixed and stained with 7-AAD and anti-BrdU antibody (APC BrdU Flow
Kit; BD Pharmingen), before flow cytometric analysis (FACS Calibur, Becton
Dickinson).
Statistical analysis. Statistical analysis was performed using the paired Student’s t
test. Significant differences of p , 0.05 are indicated by asterisks.
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